Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. raised its stake in Repare Therapeutics Inc. (NASDAQ:RPTXFree Report) by 30.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,919 shares of the company’s stock after purchasing an additional 3,493 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Repare Therapeutics were worth $180,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of RPTX. Versant Venture Management LLC purchased a new position in shares of Repare Therapeutics in the 2nd quarter valued at about $28,002,000. Bank of America Corp DE increased its holdings in shares of Repare Therapeutics by 1,913.0% in the 4th quarter. Bank of America Corp DE now owns 260,886 shares of the company’s stock valued at $3,838,000 after acquiring an additional 247,926 shares during the last quarter. Affinity Asset Advisors LLC increased its holdings in shares of Repare Therapeutics by 72.5% in the 1st quarter. Affinity Asset Advisors LLC now owns 468,905 shares of the company’s stock valued at $6,677,000 after acquiring an additional 197,127 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Repare Therapeutics by 8.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,918,026 shares of the company’s stock valued at $28,215,000 after acquiring an additional 155,283 shares during the last quarter. Finally, Bank of Montreal Can purchased a new position in shares of Repare Therapeutics in the 2nd quarter valued at about $1,470,000. Institutional investors and hedge funds own 85.09% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on RPTX. Bloom Burton downgraded Repare Therapeutics from a “buy” rating to an “accumulate” rating in a report on Tuesday, February 13th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Repare Therapeutics in a research note on Wednesday, February 21st.

Get Our Latest Research Report on RPTX

Repare Therapeutics Stock Performance

Shares of RPTX opened at $6.00 on Friday. The stock’s 50-day moving average is $6.83 and its two-hundred day moving average is $7.09. Repare Therapeutics Inc. has a 12 month low of $3.08 and a 12 month high of $13.85.

About Repare Therapeutics

(Free Report)

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.

Featured Articles

Institutional Ownership by Quarter for Repare Therapeutics (NASDAQ:RPTX)

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.